Difference between revisions of "David Haslam (GP and obesity specialist)"

From Powerbase
Jump to: navigation, search
m
Line 2: Line 2:
 
Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
 
Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
  
 +
== Activities ==
 +
 +
=== Debate over obesity drugs efficacy ===
 +
 +
On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss.  Researchers had reviewed data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
 +
 +
:Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
 +
 +
:Study leader Professor [[Gareth Williams]], professor of medicine at the [[University of Bristol]], said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
 +
 +
:‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
 +
 +
:Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
 +
 +
:Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.
 +
<ref>[http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4115938&c=2 . GPs divided on obesity drugs efficacy] Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007</ref>
  
 
==Affiliations==
 
==Affiliations==

Revision as of 23:20, 7 October 2010

Foodspin badge.png This article is part of the Foodspin project of Spinwatch.

Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the Centre for Obesity Research at Luton & Dunstable Hospital, and Chair of the UK's National Obesity Forum (NOF). [1]

Activities

Debate over obesity drugs efficacy

On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss. Researchers had reviewed data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.

Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
Study leader Professor Gareth Williams, professor of medicine at the University of Bristol, said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.

[2]

Affiliations

Books

  • Maguire, Terry., and Haslam, D. (date), The Obesity Epidemic and Its Management: A Textbook for Primary Healthcare Professionals on the Understanding, Management and Treatment of Obesity. London, England, Pharmaceutical Press.
  • Haslam, D., and Haslam, F., (2009) Fat, Gluttony and Sloth, Obesity in Art, Literature and Medicine. Liverpool, England, Liverpool University Press.

Resources

Notes

  1. National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
  2. . GPs divided on obesity drugs efficacy Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007
  3. National Obesity Forum, Dr David Haslam, last accessed 6 October 2010.
  4. LighterLife, Professor David Haslam, last accessed 6 October 2010.
  5. Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
  6. PCOS UK Executive Council , accessed 6 October 2010.
  7. Bedfordshire and Hertfordshire Postgraduate Medical School, Staff Profile Dr David W Haslam, MB BS DGM, accessed 5 October 2010.
  8. iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board , press release 24 September 2010, via Responsesource, Nilmot PR, accessed 6 October 2010.